PACS
VENTE TOTALE: 510 163 titres (~22 222 387,13 $ US)
- Insiders
- Murray Jason Hulse, Conway Patrick Hugh
- Total bought
- —
- Total sold
- $22,222,387
- Last activity
- 2026-09-09
- Last synced
-
2026-09-11 10:16:43
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-26
PACS presents a mixed but moderately constructive setup: solid fundamental improvement (margins expanding, better cash flow coverage) and a genuine earnings beat support the thesis, but the catalyst conviction is…
The first sentence of the analysis written for PACS on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 21.9% | 19.4% | 14.4% | 16.5% | 16.1% | |
| Ebit Margin | 5.9% | 3.6% | 6.7% | 9.6% | 7.4% | |
| Ebitda Margin | 6.9% | 4.6% | 7.5% | 10.5% | 8.0% | |
| Operating Profit Margin | 5.9% | 3.0% | 6.7% | 9.5% | 7.1% | |
| Pretax Profit Margin | 5.4% | 2.5% | 5.1% | 8.5% | 7.0% | |
| Continuous Operations Profit Margin | 3.6% | 1.4% | 3.6% | 6.2% | 4.1% | |
| Net Profit Margin | 3.6% | 1.4% | 3.6% | 6.2% | 4.1% | |
| Bottom Line Profit Margin | 3.6% | 1.4% | 3.6% | 6.2% | 4.1% | |
| Current Ratio | 1.068 | 0.959 | 1.580 | 1.056 | 0.000 | |
| Quick Ratio | 1.068 | 0.959 | 1.580 | 1.056 | 0.000 | |
| Solvency Ratio | 0.053 | 0.021 | 0.041 | 0.072 | 0.000 | |
| Cash Ratio | 0.197 | 0.161 | 0.161 | 0.120 | 0.000 | |
| Price To Earnings Ratio | 31.211 | 34.500 | 30.667 | 23.000 | 71.875 | |
| Price To Earnings Growth Ratio | 0.140 | -0.699 | -1.227 | 0.108 | 0.000 | |
| Forward Price To Earnings Growth Ratio | 0.140 | -0.699 | -1.227 | 0.108 | 0.000 | |
| Price To Earnings Diluted Ratio | 31.467 | 34.500 | 30.667 | 23.000 | 71.875 | |
| Price To Earnings Diluted Growth Ratio | 0.142 | -0.699 | -1.227 | 0.108 | 0.000 | |
| Price To Book Ratio | 6.333 | 2.710 | 35.927 | 54.261 | 0.000 | |
| Price To Sales Ratio | 1.134 | 0.470 | 1.110 | 1.426 | 2.960 | |
| Price To Free Cash Flow Ratio | 20.065 | 109.671 | 192.771 | 49.510 | -51.944 | |
| Price To Operating Cash Flow Ratio | 14.833 | 5.234 | 54.218 | 37.289 | 59.954 | |
| Debt To Assets Ratio | 0.622 | 0.668 | 0.798 | 0.782 | 0.000 | |
| Debt To Equity Ratio | 3.666 | 4.934 | 29.179 | 30.254 | 0.000 | |
| Debt To Capital Ratio | 0.786 | 0.831 | 0.967 | 0.968 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.267 | 0.261 | 0.882 | 0.873 | 0.000 | |
| Financial Leverage Ratio | 5.898 | 7.389 | 36.543 | 38.681 | 0.000 | |
| Working Capital Turnover Ratio | 375.928 | 36.345 | 21.274 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | 0.404 | 0.375 | 0.139 | 0.191 | 0.000 | |
| Operating Cash Flow Sales Ratio | 0.076 | 0.090 | 0.020 | 0.038 | 0.049 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.739 | 0.048 | 0.281 | 0.753 | -1.154 | |
| Debt Service Coverage Ratio | 8.304 | 0.698 | 2.823 | 2.282 | 0.000 | |
| Interest Coverage Ratio | 10.915 | 2.776 | 4.162 | 8.981 | 15.794 | |
| Short Term Operating Cash Flow Coverage Ratio | 90.572 | 2.342 | 3.787 | 1.509 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.116 | 0.105 | 0.023 | 0.048 | 0.000 | |
| Capital Expenditure Coverage Ratio | 3.835 | 1.050 | 1.391 | 4.051 | 0.464 | |
| Dividend Paid And Capex Coverage Ratio | 3.835 | 0.958 | 0.505 | 1.114 | 0.324 | |
| Dividend Payout Ratio | 0.000 | 0.605 | 0.712 | 0.401 | 1.122 | |
| Enterprise Value Multiple | 25.357 | 28.206 | 26.560 | 20.874 | 0.000 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 21.9% | ▲2.5% | ▲4.3% |
| Ebit Margin | 5.9% | ▲2.3% | ▼-0.8% |
| Ebitda Margin | 6.9% | ▲2.4% | ▼-0.6% |
| Operating Profit Margin | 5.9% | ▲2.8% | ▼-0.6% |
| Pretax Profit Margin | 5.4% | ▲2.9% | ▼-0.3% |
| Continuous Operations Profit Margin | 3.6% | ▲2.3% | ▼-0.2% |
| Net Profit Margin | 3.6% | ▲2.3% | ▼-0.2% |
| Bottom Line Profit Margin | 3.6% | ▲2.3% | ▼-0.2% |
| Current Ratio | 1.068 | ▲0.109 | ▲0.135 |
| Quick Ratio | 1.068 | ▲0.109 | ▲0.135 |
| Solvency Ratio | 0.053 | ▲0.032 | ▲0.016 |
| Cash Ratio | 0.197 | ▲0.036 | ▲0.069 |
| Price To Earnings Ratio | 31.211 | ▼-3.289 | ▼-7.039 |
| Price To Earnings Growth Ratio | 0.140 | ▲0.839 | ▲0.475 |
| Forward Price To Earnings Growth Ratio | 0.140 | ▲0.839 | ▲0.475 |
| Price To Earnings Diluted Ratio | 31.467 | ▼-3.033 | ▼-6.835 |
| Price To Earnings Diluted Growth Ratio | 0.142 | ▲0.842 | ▲0.477 |
| Price To Book Ratio | 6.333 | ▲3.623 | ▼-13.513 |
| Price To Sales Ratio | 1.134 | ▲0.663 | ▼-0.286 |
| Price To Free Cash Flow Ratio | 20.065 | ▼-89.606 | ▼-43.950 |
| Price To Operating Cash Flow Ratio | 14.833 | ▲9.599 | ▼-19.473 |
| Debt To Assets Ratio | 0.622 | ▼-0.046 | ▲0.048 |
| Debt To Equity Ratio | 3.666 | ▼-1.268 | ▼-9.941 |
| Debt To Capital Ratio | 0.786 | ▼-0.046 | ▲0.075 |
| Long Term Debt To Capital Ratio | 0.267 | ▲0.006 | ▼-0.190 |
| Financial Leverage Ratio | 5.898 | ▼-1.491 | ▼-11.804 |
| Working Capital Turnover Ratio | 375.928 | ▲339.583 | ▲289.219 |
| Operating Cash Flow Ratio | 0.404 | ▲0.028 | ▲0.182 |
| Operating Cash Flow Sales Ratio | 0.076 | ▼-0.013 | ▲0.022 |
| Free Cash Flow Operating Cash Flow Ratio | 0.739 | ▲0.692 | ▲0.606 |
| Debt Service Coverage Ratio | 8.304 | ▲7.605 | ▲5.482 |
| Interest Coverage Ratio | 10.915 | ▲8.140 | ▲2.390 |
| Short Term Operating Cash Flow Coverage Ratio | 90.572 | ▲88.230 | ▲70.930 |
| Operating Cash Flow Coverage Ratio | 0.117 | ▲0.011 | ▲0.058 |
| Capital Expenditure Coverage Ratio | 3.835 | ▲2.785 | ▲1.677 |
| Dividend Paid And Capex Coverage Ratio | 3.835 | ▲2.877 | ▲2.488 |
| Dividend Payout Ratio | 0.000 | ▼-0.605 | ▼-0.568 |
| Enterprise Value Multiple | 25.358 | ▼-2.848 | ▲5.158 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $6.00B | $1.92B | $3.45B | $3.45B | $3.45B | |
| Enterprise value | $9.27B | $5.27B | $6.18B | $5.32B | $0 | |
| EV / Sales | 1.75x | 1.29x | 1.99x | 2.20x | 0.00x | |
| EV / Op. cash flow | 22.93x | 14.34x | 97.10x | 57.45x | 0.00x | |
| EV / Free cash flow | 31.02x | 300.37x | 345.24x | 76.28x | 0.00x | |
| EV / EBITDA | 25.36x | 28.21x | 26.56x | 20.87x | 0.00x | |
| Net debt / EBITDA | 8.96x | 17.91x | 11.73x | 7.33x | 0.00x | |
| Current ratio | 1.07x | 0.96x | 1.58x | 1.06x | 0.00x | |
| Income quality | 2.11x | 6.59x | 0.56x | 0.61x | 1.20x | |
| Graham number | $13 | $6 | $3 | $3 | $0 | |
| Graham net-net | -$25 | -$26 | -$19 | -$13 | $0 | |
| Tax burden | 67.3% | 54.9% | 71.7% | 72.7% | 58.9% | |
| Interest burden | 91.8% | 69.6% | 75.9% | 89.0% | 93.9% | |
| Working capital | $68.3M | -$40.2M | $265.2M | $27.3M | $0 | |
| Invested capital | $4.31B | $4.01B | $2.92B | $1.86B | $0 | |
| Return on assets | 3.4% | 1.1% | 3.2% | 6.1% | 0.0% | |
| Operating ROA | 5.7% | 2.8% | 7.0% | 0.0% | 0.0% | |
| Return on tangible assets | 3.5% | 1.1% | 3.3% | 6.3% | 0.0% | |
| Return on equity | 20.2% | 7.9% | 117.4% | 236.5% | 0.0% | |
| Return on invested capital | 4.4% | 1.5% | 4.7% | 7.7% | 0.0% | |
| Return on capital employed | 6.8% | 2.9% | 6.8% | 11.6% | 0.0% | |
| Earnings yield | 3.2% | 2.9% | 3.3% | 4.4% | 1.4% | |
| Free cash flow yield | 5.0% | 0.9% | 0.5% | 2.0% | -1.9% | |
| Capex / Op. cash flow | 26.1% | 95.2% | 71.9% | 24.7% | 215.4% | |
| Capex / Depreciation | 189.4% | 857.2% | 178.6% | 102.5% | 1734.8% | |
| Capex / Sales | 2.0% | 8.6% | 1.5% | 0.9% | 10.6% | |
| SG&A / Sales | 7.8% | 8.4% | 6.9% | 6.2% | 8.3% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 1.0% | 2.8% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 1.2% | 1.3% | 1.9% | 2.5% | 0.0% | |
| Days sales outstanding | 48d | 64d | 70d | 63d | 0d | |
| Days payables outstanding | 17d | 19d | 19d | 20d | 0d | |
| Operating cycle | 48d | 64d | 70d | 63d | 0d | |
| Cash conversion cycle | 31d | 45d | 51d | 43d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+211.8%EV / Sales ▲+36.1%EV / EBITDA ▼-10.1%EV / Op. cash flow ▲+8.597Earnings yield ▲+0.003Graham number ▲+6.500
Profitability
Return on equity ▲+0.124Return on assets ▲+0.024Return on invested capital ▲+0.029Return on capital employed ▲+0.039Operating ROA ▲+0.029Income quality ▼-4.477Tax burden ▲+0.124
Efficiency
Days sales outstanding ▼-15.495Days payables outstanding ▼-2.390Operating cycle ▼-15.495Cash conversion cycle ▼-13.105Capex / Sales ▼-0.066R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.109Net debt / EBITDA ▼-8.951Working capital ▲+108480000.000Invested capital ▲+293653000.000Intangibles / Total assets ▼-0.001
Change over 5 years
Valuation
Market cap ▲+73.6%EV / Sales n/aEV / EBITDA n/aEV / Op. cash flow n/aEarnings yield ▲+0.018Graham number n/a
Profitability
Return on equity n/aReturn on assets n/aReturn on invested capital n/aReturn on capital employed n/aOperating ROA n/aIncome quality ▲+0.910Tax burden ▲+0.085
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales ▼-0.086R&D / Sales n/a
Balance-sheet strength
Current ratio n/aNet debt / EBITDA n/aWorking capital n/aInvested capital n/aIntangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-08 PACS Expands Florida Footprint With 32-Facility Acquisition PACS plans to acquire operations of 32 Florida skilled nursing facilities, adding 4,049 licensed beds and establishing a statewide network.
- 2026-09-04 Bank of New York Mellon Corp Takes Position in PACS Group, Inc. $PACS Bank of New York Mellon Corp bought a new stake in PACS Group, Inc. (NYSE: PACS) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 192,210 shares of the company''s stock, valued at approximately $8,196,000. Bank of New York Mellon Corp
- 2026-09-01 PACS Group: The Peer Check Stopped Me From Calling It Cheap I rate PACS a Buy and value the shares at $49.58, about 17% above the August 31 closing price. Q2 revenue rose 9.1%, operating income grew 35.8%, and same-store occupancy reached 90.6%. Eduro adds 3,633 beds. My 2027 model includes $260 million of incremental revenue after a 27% haircut.
- 2026-09-01 PACS Group to Acquire Operations of 32 Facilities Across Florida and Closes on Additional Previously Announced Eduro Facilities SALT LAKE CITY--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS) announced today that subsidiaries of the Company have entered into definitive agreements to acquire the operations of 32 skilled nursing facilities across Florida. The facilities will be leased from subsidiaries of one of our existing REIT landlords, Omega Healthcare Investors, Inc. (NYSE: OHI).The facilities have a combined 4,049 licensed skilled nursing beds and are deeply integrated into local healthcare networks throughout Florid.
- 2026-08-25 Allegion Redefines Commercial Access Control with the Schlage XE360™ Series featuring RealSync™ Persistent Wi-Fi Technology Allegion Redefines Commercial Access Control with the Schlage XE360⢠Series featuring RealSync⢠Persistent Wi-Fi Technology P
- 2026-08-25 Zacks Industry Outlook CareDx, BrightSpring and PACS CareDx, BrightSpring and PACS have been highlighted in this Industry Outlook article.
- 2026-08-24 3 Medical Service Stocks Resilient Amid Persistent Workforce Shortage CareDx, BrightSpring and PACS Group are positioned for growth as digital health expands and workforce shortages reshape medical services.
- 2026-08-19 Amid Legal Risks, This Company Is Still Rated a Buy When investors look for stocks riding the aging of America, they might look at hospital chains, pharmacy benefit managers, or dividend-paying healthcare REITs.
- 2026-08-13 Wall Street Analysts See a 25.73% Upside in PACS Group, Inc. (PACS): Can the Stock Really Move This High? The consensus price target hints at a 25.7% upside potential for PACS Group, Inc. (PACS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 2026-08-08 PACS Group Q2 Earnings Call Highlights PACS Group NYSE: PACS reported second-quarter 2026 revenue growth of 9.1% and adjusted EBITDA growth of 25% from a year earlier, citing higher occupancy, improved skilled nursing patient mix and continued progress across acquired facilities as they mature within its operating model.